MGC Pharmaceuticals Limited Corporate Update - Board and UK Adviser Changes (9890A)
May 30 2023 - 2:01AM
UK Regulatory
TIDMMXC
RNS Number : 9890A
MGC Pharmaceuticals Limited
30 May 2023
Corporate Update - Board and UK Adviser Changes
30 May 2023
ASX/LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a
European based pharmaceutical company specialising in the
production and development of plant inspired medicines, announces
the following changes to the Board and its lead UK advisers, as a
further development in its pharmaceutical business plan.
Mr Brett Mitchell and Mr Nativ Segev, will step down from the
Board, reflecting the changing direction of the Company as MGC
Pharmaceuticals moves away from the medicinal cannabis sector
toward a more pharma-focused business strategy effective 1 June
2023. Dr Stephen Parker, currently Non-Executive Director of the
Company, will replace Mr Mitchell as interim Non-Executive Chair.
The Company will appoint a new Australian non-executive director
ensuring compliance with section 201A(2) of the Corporations Act
and the ASX Listing Rules.
Oberon Capital has been appointed as joint broker in the UK with
immediate effect alongside Peterhouse Capital.
IFC Advisory has been appointed as the Company's new UK-based
Public and Investor Relations advisers. The IFC team have in-depth
experience in the pharmaceutical sector and will support MGC in its
stated forward trajectory.
Roby Zomer, Managing Director and CEO of MGC Pharmaceuticals,
commented : "The changes to our key advisers reflect the ongoing
work we have undertaken in advancing our pharmaceutical strategy
both in the UK and in Australia."
"I would like to thank founding Board members, Nativ and Brett,
for their efforts and support as we have grown the Company over the
past 8 years, and we will continue to value Brett's insight in his
new role as an advisor to the Board."
-Ends-
Authorised for release by the board of directors, for further
information please contact:
MGC Pharmaceuticals Ltd MGC Pharmaceuticals Ltd
Roby Zomer Arron Canicais / Rowan
CEO & Managing Director Harland
+61 8 6382 3390 Joint Company Secretaries
info@mgcpharma.co.uk +61 8 6382 3390
info@mgcpharma.co.uk
UK Brokers UK Brokers
Peterhouse Capital Oberon Capital
Charles Goodfellow / Lucy Williams Aimee McCusker / Adam Pollock
/ Duncan Vasey +44 203 179 5300
+44 207 469 0930 aimeemccusker@oberoninvestments.com
cg@peterhousecap.com / lw@peterhousecap.com adampollock@oberoninvestments.com
UK IR/PR Advisers
IFC Advisory
Graham Herring / Tim Metcalfe / Zach
Cohen
+44 203 934 6630
mgcpharma@investor-focus.co.uk
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based
pharmaceutical company, focused on developing and supplying
accessible and ethically produced plant inspired medicines,
combining in-house research with innovative technologies, with the
goal of finding or producing treatments to for unmet medical
conditions.
The Company's founders and executives are key figures in the
global pharmaceuticals industry and the core business strategy is
to develop and supply high quality plant inspired medicines for the
growing demand in the medical markets in Europe, North America and
Australasia.
MGC Pharma has a robust development pipeline targeting two
widespread medical conditions and has further products under
development.
MGC Pharma has partnered with renowned institutions and academia
to optimise the development of targeted plant inspired medicines,
to be produced in the Company's EU-GMP Certified manufacturing
facilities.
MGC Pharma has a growing patient base in Australia, the UK,
Brazil and Ireland and has a global distribution footprint via an
extensive network of commercial partners meaning that it is poised
to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDZZGFKKGNGFZG
(END) Dow Jones Newswires
May 30, 2023 02:01 ET (06:01 GMT)
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From Apr 2024 to May 2024
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From May 2023 to May 2024